CSF1R and intrahepatic cholangiocarcinoma: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Conducts a Secondary Clinical Trial of Durvalumab (MEDI4736) combined with CSF-1R Inhibitor (SNDX-6532) following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma (NCT04301778).